JPMorgan has resumed its coverage of NovoCure (NASDAQ: NVCR) with a neutral rating, according to a research note published on Friday. The US-based medical technology company, known for its tumour-treating electric field (TTF) therapy used in oncology, has drawn renewed attention from analysts as it expands its clinical pipeline.
The neutral rating suggests that JPMorgan sees limited upside potential in the near term, with the stock currently trading at levels that already reflect much of the company's growth prospects. NovoCure's shares have been volatile over the past year, influenced by regulatory developments and trial results for its Optune device, which is approved for glioblastoma and other solid tumours.
For UK investors, the coverage resumption is a reminder of the global nature of healthcare investing. While NovoCure is not listed in London, many UK pension funds and investment trusts hold US-listed equities as part of diversified portfolios. The neutral rating may temper enthusiasm among retail investors who have been watching the stock's recent rally.
Analysts at JPMorgan noted that NovoCure's technology is innovative, but the company faces challenges including reimbursement hurdles and competition from emerging therapies. The neutral stance implies that the risk-reward profile is balanced, with no imminent catalyst expected to drive a significant re-rating.
In the broader healthcare sector, the FTSE 100's pharmaceutical and biotech components have also seen mixed performance. Shares of AstraZeneca and GSK have been relatively stable, while smaller biotech firms have experienced greater volatility. The NovoCure coverage resumption highlights the ongoing investor interest in oncology-focused medtech, a segment that could benefit from an ageing population and rising cancer incidence.